About a week ago, the International Conference on Gastrointestinal Tracts was held in the United States.
The conference presented results from a Phase I / II clinical trial that examined a combination of two drugs, one biologically called Cyramza® and the other, immunotherapy called Opdivo®, as treatment for metastatic gastric cancer patients who failed on a number of standard treatment lines.
Both of these drugs are FDA approved.
Patients with Stage 4 metastatic gastric cancer, usually receive chemotherapy and when, as expected, these treatments fail, next treatment options are very limited and the expected life expectancy is very short
Cyramza® was given at 8 mg/kg every two weeks and its dosage was given at 3 mg/kg or 1 mg/kg (option in the study for patient’s decision), once every two weeks.
It is known that immunotherapies are associated with high levels of PD-L1. However, the study demonstrated that life prolongation was the same in patients with low PD-L1 and in patients with high PD-L1!
To me, it’s amazing! Because it is such a devastating and horrible disease!
In addition, in one-third of patients, the disease shrieked. In another third, the disease was stopped!
This is progress!!!! This is it!!! And we are here for you!